(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.10%) $78.19
(0.89%) $2.16
(-0.24%) $2 303.10
(-0.03%) $26.68
(-0.71%) $958.45
(0.06%) $0.929
(-0.02%) $10.87
(0.03%) $0.797
(0.00%) $91.45
Quarter results tomorrow
(amc 2024-05-07)
Expected move: +/- 6.00%
0.64% $ 1.580
Live Chart Being Loaded With Signals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 9 703.00 |
Średni wolumen | 10 070.00 |
Kapitalizacja rynkowa | 22.40M |
EPS | $0 ( 2024-03-05 ) |
Następna data zysków | ( $0 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.59 |
ATR14 | $0.0100 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Krogulski Kenneth | Buy | 5 000 | Common Stock |
2024-03-25 | Jones James | Buy | 1 000 | Common Stock |
2024-03-25 | Galante Joseph C | Buy | 1 000 | Common Stock |
2024-03-25 | Young Caroline | Buy | 1 000 | Common Stock |
2024-03-25 | Brown Martin S Jr | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
64.38 |
Last 100 transactions |
Buy: 135 322 | Sell: 29 102 |
Cumberland Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ATER | 0.968 |
PHUN | 0.966 |
WATT | 0.965 |
OGI | 0.964 |
ADTX | 0.964 |
RKDA | 0.963 |
BNGO | 0.961 |
DISH | 0.961 |
ISUN | 0.961 |
BZUN | 0.961 |
10 Najbardziej negatywne korelacje | |
---|---|
MSDA | -0.973 |
BRIV | -0.965 |
ZING | -0.965 |
TIOAU | -0.965 |
ADAL | -0.964 |
VMGA | -0.958 |
VLAT | -0.958 |
BRIVU | -0.957 |
TIOA | -0.954 |
APXI | -0.952 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cumberland Finanse
Annual | 2023 |
Przychody: | $39.55M |
Zysk brutto: | $28.55M (72.18 %) |
EPS: | $-0.440 |
FY | 2023 |
Przychody: | $39.55M |
Zysk brutto: | $28.55M (72.18 %) |
EPS: | $-0.440 |
FY | 2022 |
Przychody: | $42.01M |
Zysk brutto: | $32.89M (78.29 %) |
EPS: | $-0.390 |
FY | 2021 |
Przychody: | $35.99M |
Zysk brutto: | $27.17M (75.51 %) |
EPS: | $-0.240 |
Financial Reports:
No articles found.
Cumberland
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej